Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 17/20 | 0.55 |
| ▸ | WDR77 | Q9BQA1 | 17/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14628540 | 0.89 | PRMT5 (0.59) | PRMT5WDR77ADORA2AADK | |
| SCHEMBL13864255 | 0.88 | PRMT5 (0.56) | PRMT5WDR77ADORA2AADK | |
| SCHEMBL12963414 | 0.88 | PRMT5 (0.54) | PRMT5WDR77ADORA2AADK | |
| SCHEMBL13020658 | 0.88 | PRMT5 (0.54) | PRMT5WDR77ADORA2AADK | |
| SCHEMBL13483564 | 0.87 | PRMT5 (0.68) | PRMT5WDR77ADORA2AADK | |
| SCHEMBL13867345 | 0.85 | PRMT5 (0.57) | PRMT5WDR77ADORA2AADK | |
| SCHEMBL13482921 | 0.84 | PRMT5 (0.56) | PRMT5WDR77ADORA2AADK | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL12149452 | 0.84 | ADORA2A (0.67) | PRMT5WDR77ADORA2AADK | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL6422519 | 0.84 | ADORA2A (0.67) | PRMT5WDR77ADORA2AADK | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL13772636 | 0.84 | ADORA2A (0.67) | PRMT5WDR77ADORA2AADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060264389-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | BHAT BALKRISHEN | 2006-11-23 | — | — | US | disclosed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264389-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 444/4885WDR77 1752/4885ADORA2A 385/4885 |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | ITPA, PNP, NUDT1 | PRMT5 1470/4885WDR77 1575/4885ADORA2A 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.